^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Simulect (basiliximab)

    i
    Associations
    News

    Trials

    Company:
    Novartis
    Drug class:
    CD25 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Stem Cell Transplantation for Patients With Multiple Myeloma (NCT01526096)
    Phase 1
    University of Chicago
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    07/12/2011
    Primary completion :
    09/12/2025
    Completion :
    09/12/2025
    IL2RA • CD4 • FOXP3 • ISG20
    |
    melphalan • Simulect (basiliximab) • plerixafor
    Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (NCT02342782)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/19/2024
    Initiation :
    06/08/2020
    Primary completion :
    09/18/2020
    Completion :
    12/31/2024
    ALK • CD34
    |
    cytarabine • etoposide IV • etoposide oral • carmustine • melphalan • Simulect (basiliximab)
    Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (NCT01476839)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/19/2024
    Initiation :
    11/09/2012
    Primary completion :
    07/24/2021
    Completion :
    12/31/2024
    CD34
    |
    cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab)
    90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT05139004)
    Phase 1
    City of Hope Medical Center
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    07/19/2022
    Primary completion :
    12/13/2024
    Completion :
    12/13/2024
    FLT3 • NPM1 • IL2RA • ISG20
    |
    MLL rearrangement • IL2RA expression • Chr t(9;11)
    |
    melphalan • fludarabine IV • Kepivance (palifermin) • Simulect (basiliximab)
    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (NCT04871607)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    06/22/2023
    Initiation :
    11/02/2021
    Primary completion :
    10/02/2027
    Completion :
    10/02/2027
    CD34
    |
    cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab) • Starasid (cytarabine ocfosfate)
    Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe) (NCT00626483)
    Phase 1
    Gary Archer Ph.D.
    Completed
    Last update posted :
    03/09/2021
    Initiation :
    04/24/2007
    Primary completion :
    07/06/2016
    Completion :
    07/06/2016
    IL2RA • CD4 • IL7R • NCAM1 • ISG20
    |
    NCAM1 expression
    |
    temozolomide • Simulect (basiliximab) • umitrelimorgene autodencel (ITI-1000)
    Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission (NCT01842139)
    Phase 1
    University of Chicago
    Completed
    Last update posted :
    03/09/2018
    Initiation :
    12/05/2011
    Primary completion :
    02/02/2015
    Completion :
    03/01/2018
    CD8 • IFNG • WT1 • FOXP3
    |
    FOXP3 expression
    |
    Zeltherva (galinpepimut-S) • Hiltonol (poly-ICLC) • Simulect (basiliximab)
    Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery (ZAP IT) (NCT00626015)
    Phase 1
    John Sampson
    Completed
    Last update posted :
    01/21/2016
    Initiation :
    03/01/2007
    Primary completion :
    02/01/2013
    Completion :
    02/01/2013
    IL2RA • CD4 • IL7R • ISG20
    |
    EGFRvIII expression
    |
    temozolomide • Rintega (rindopepimut) • Simulect (basiliximab) • Zinbryta (daclizumab)